Top CFO Executive Search Firm in New Delhi for Pharma & Biotech — 2026

The capital region is a significant base for Indian pharmaceuticals — formulations and generics companies, CDMO and API businesses, a growing biotech and specialty scene, and consumer-health players, with the central drug regulator and health ministry nearby. The pharma CFO mandate is shaped by global complexity and capital intensity. A generics or formulations CFO manages multi-currency global revenue, transfer pricing, R&D and ANDA capitalisation, price erosion in regulated markets and the working capital of a global supply chain; a CDMO or API CFO runs capacity capex, customer-contract economics and quality-driven cost; a biotech or specialty CFO funds a research-led business through milestones, partnerships and venture capital. Across all, the CFO must fund global growth and capex while managing currency, regulatory and pricing risk and meeting the disclosure standard of listed and globally regulated businesses. The defining scarcity is the finance leader who commands global pharma finance — currency, transfer pricing, R&D capitalisation — and the capital discipline the industry's cycles demand.

Compensation is cash-led with performance pay and long-term incentives in established companies, equity-weighted in biotech and venture-backed settings. The brief codifies the construction. The stakeholder map runs from promoters, boards, auditors and lenders to global clients, partners and investors. References reach to boards, auditors and finance peers, because the question that decides these mandates — can this leader fund and de-risk global pharma through the cycle — is answered by those who have governed that balance sheet.